Mice were infected i.c. or i.p. by an avirulent clone of Semliki Forest virus at various times before or after the i.p. administration of a single dose of cyclophosphamide. Consequent changes in the patterns of viraemia and antibody production are interpreted in terms of the potentiation of the initial infection or the decreased resistance to subsequent lethal challenge.
INTRODUCTION
Recent studies (Bradish & Allner, I972; Walder & Bradish, 1975) have demonstrated that serologically indistinguishable or closely related strains of virus may express distinct patterns of invasion and virulence in appropriate hosts, and that the interactions (Bradish, Allner & Maber, 1972) which control the expression of virulence may be determined early after infection and before many responses can be observed.
The early mechanisms in host-response and the expression of virulence may be studied in terms of virus dose, heterogeneity and route of infection (Bradish et al. I972) , and through the distinct responses of hosts of different species (Bradish, Allner & Maber, I97i ; Calisher & Maness, I974) , or of defined strains and ages (Darnell, Koprowski & Lagerspetz, 1974; Walder & Bradish, 1975) . A further approach involves the modification of host susceptibility by immunosuppression (Nathanson & Cole, I97I) or immunomodification (Allner et al. 1974) which, if appropriate drugs are applied as minimal single doses, is time-limited and reversible and more easily related to individual responses at critical times or sites. Such studies with cyclophosphamide are reported in this paper, and with Myocrisin and 1-asparaginase in the following paper (Bradish, Allner & Fitzgeorge, 1975) .
The term 'immunomodification' is used here and in the next paper to embrace several distinct changes (immunosuppression, immunoenhancement, potentiation, enhancement of infection) which may be expressed through host-response and the development of immunity. Several such modifications may be observed as the effects of a single drug and these may depend upon combinations of specific or non-specific, humoral or cellular mechanisms. 226 C.J. BRADISH, K. ALLNER AND R. FITZGEORGE
METHODS
Virus strains. The strains of Semliki Forest virus (SFV) were specified in earlier studies (Bradish et al. I97I, 1972; Bradish & Allner, 1972) . Briefly, the clonally specified avirulent strain A774.CI kills mice below I5 days old (~ I p.f.u./LDso) but immunizes mice above 30 days old (~ Ioo p.f.u./PDs0 and > Io s p.f.u./LDs0 i.c.). The virulent strain LIo.CI kills mice of any age (~ I p.f.u./LDs0 i.p. for mice up to I5 days old, ~ Ioo p.f.u./LD~0 i.p. for mice above 30 days old).
Assay of titus infectivity. This was by plaque counting in agar suspensions of primary chick embryo cells (Bradish et al. I97I) at the time of the mouse inoculations of the same samples.
Assay of virus, antibody and interferon in blood and tissues. After removal of blood and tissues at various times, individual infectivities were assayed by plaque counting and the results assessed for blood-in-tissues errors as described by Bradish & Allner (I972) . Interferon and antibody activities were estimated by plaque reduction in agar suspensions of mouse L cells and chick embryo cells, respectively. Interferon assays were standardised by the use of NIH (U.S.A.) or MRC (U.K.) standards (Bradish & Allner, 197o) and antibody assays through equivalence and affinity-column procedures (Fitzgeorge & Bradish, 1973) .
Procedures in mice. Mice were obtained from Allington Farm, Porton, and were either Porton random-bred (PR strain) or limited outbred (A2G, C57, C3H). Mice of specified ages (_+ Io %) were used in groups of Io or more for each drug treatment and virus sample. The cyciophosphamide employed was obtained as Endoxana from Ward, Blenkinsop & Co. Ltd of Wembley. Drug and virus were prepared at appropriate concentrations in Parker's medium 199 with Io % pre-tested calf-serum or 0"3 % BSA, pH 7"4. Single doses of 4 mg of the drug were administered at appropriate times by intraperitoneal (i.p.) inoculation of o.I ml. Zero-time is defined as the time of virus inoculation in o'o25 ml i.p. or intracerebrally (i.c.) . Mice were then scored daily for clinical signs, bled from the retro-orbital plexus, or killed for recovery of tissues, as indicated above. At I4 to 24 days after primary infection the mice were challenged by the i.p. or i.c. injection of Ioo to Iooo LDs0 of the virulent strain LIo.CI of SFV. Survivors at 30 to 40 days after this lethal challenge were regarded as protected (P) by the primary infection.
In control mice receiving only 4 mg i.p. of cyclophosphamide there were fewer than 5 % excess deaths within 8 weeks.
RESULTS

Assessment and presentation of results
Within each group of mice receiving either virus, or virus and drug under standard conditions, the following responses were scored: D, the percentage of animals dying as a result of primary infection, and before lethal challenge on the I4th to 24th day; S, the percentage of animals susceptible to lethal challenge and dying before termination of observation on the 3oth to 4oth day; P, the percentage of animals defined as protected through immunity to the lethal-challenge. The changed responses due to immunomodification by drug were then assessed as primary potentiation for the increased percentage of animals dying following primary infection and before lethal challenge. Secondary potentiation is the increased percentage of animals susceptible to secondary or challenge infection. This last term defines the extent to which the protective responses induced by the primary avirulent infection may Broken lines show assays on blood for: B, viraemia as log (p.f.u./ml blood) for virulent or avirulent infected mice; I, interferon activity as log (standardized units/ml blood) for virulent or avirulent infected mice; N, serum neutralization index (SNI) as log (neutralization units/ml blood) for avirulent infected mice. In view of the absolute insensitivity of neutralization assays in comparison with infectivity assays, the additional scale shows the equivalent values of N as log (immunoglobulin molecules/ml blood). Solid lines show assays of infectivity for brains and spleens as log (p.f,u./organ) for virulent (V) or avirulent (A) infected mice. Virulent infections result in death at 6±o'z days for about 9o % of mice, and avirulent infections are benign for about 85 % of mice (see Table 3 ).
be impaired or may decline rapidly following drug imposed immunomodification. Clearly
D+P+S
= lOO% and
Primary potentiation % + secondary potentiation % = IOO-(% of animals with no detected change in response).
A correction factor must be applied if the secondary or challenge infection by virulent virus fails to kill all animals in a susceptible control group. Thus if the challenge infection of a control group shows C % lethality, then all P proportions must be corrected to
-(--C-I) S, and all S proportions to -~-s. Typical assessments are shown in Table 3- A further important consequence of immunomodification may be the changed survival times for animals which die following primary infection (D %) or following secondary lethal challenge (S%). Such data are also shown in Table 3 and are discussed later.
Early responses to virulent or avirulent strains of SFV
The median patterns of the early responses of mice to infection by defined strains of SFV are shown in Fig. I . This expands a previous report (Bradish & Allner, I972) on the scatter of individual early responses and provides the background against which immunomodifications can be compared.
In mice of 3o to 5o days old infected i.p. by Iooo p.f.u, of an SFV strain at any level of virulence, there is an early and parallel rise and fall in blood infectivity and blood interferon (broken lines in Fig. I ) which mark the replication of virus in many primary tissue sites, particularly muscle (Murphy, Harrison & Collin, I97o; Pusztai, Gould & Smith, I97i ) . This is maximal at about 35 h after i.p. infection for 6o % of fastest responding mice.
The recovery of virus replicating in the brain (solid lines in Fig. I ) is first significant at about 48 h after i.p. infection when viraemia is already falling rapidly. Infections with virulent or avirulent strains of SFV may first be distinguished at about 7o h after infection when most virulent infected mice have high brain infectivity (~ IO 9 p.f.u./brain), and are proceeding to paralysis and death. At these times the avirulent infected mice show no clinical signs, falling brain infectivity (maximum ~ IO 6"5 p.f.u./brain), rising blood antibody levels and are fully protected against even i.e. challenge by virulent virus.
The involvement of the spleen is maximal at 75 to Ioo h after i.p. infection. At this time avirulent or virulent infections are characterised by more or less than m a5 p.f.u./spleen, respectively. Virus is rarely recoverable from avirulent infected mice after 4 to 5 days in blood, 5 to 6 days in spleen, or 8 to 9 days in brain.
In the experiments to be reported with normal and cyclophosphamide treated mice, particular attention has been given to the events which may influence or control the terminal response (expression of virulence) and which precede the first significant divergence, at 3 to 4 days after infection, of the brain or spleen infectivities in virulent and avirulent infected mice (Fig. I ).
Multiple effects of single doses of cyclophosphamide
To determine the relationships between several criteria of response, cyclophosphamide was administered as a single dose at various times from 3 days before to 3 days after infection i.p. by Io 6 p.f.u, of virus of the avirulent A774.CI strain. Groups of 2o mice so treated were bled on the seventh day after infection since at this time ( Fig. I ) mice receiving only virus have negligible viraemia and high antibody levels associated with strong protection against challenge (Fig. 2 , Table 2 ).
The results (Fig. 2) show the control mice without drug at both ends of the time scale to 'emphasise the reversibility of the immunomodifications imposed by cyclophosphamide: this cannot be tested beyond about day -5 for 37 days old mice in view of the immaturity of mice under 3o days old (Walder & Bradish, I975) . Other similar experiments confirmed that cyclophosphamide administered from 3 to 5 days, or later, after virus infection failed to modify the normal development of antibody activity or pattern of response (Fig. I) .
It is clear from Fig. 2 a that the observation of viraemia at day 7 or beyond is a feature of cyclophosphamide administration within the brief period from about day o to + 3. This is associated with depression of antibody synthesis to o'3 % or less of normal values. Primary potentiation was maximal at about 50 % when cyclophosphamide was administered once from day + I to -3 ( Fig. 2 b) or beyond. In contrast, secondary potentiation and viraemia were maximal when cyclophosphamide was administered within about a day of virus infection.
Thus immunomodification by cyclophosphamide is of at least two types. Administration before virus infection i.p. shows potentiation of disease as an increased incidence of primary deaths associated with antibody synthesis and normal patterns of brief viraemia (Fig. I) . Conversely, cyclophosphamide administered within about 2 days following virus infection causes a maximal reduction in the resistance to challenge infection (secondary potentiation) associated with falling primary potentiation, persistence of high levels of viraemia and suppression of antibody synthesis. Thus, these potentiations of an avirulent infection by cyclophosphamide are not related directly to changed levels of viraemia or antibody synthesis. It must be noted that the different patterns of replication in the brains or spleens of mice of virulent and avirulent strains of virus are first distinguished at about 3 days after x6-2 Antibody activity as log (p.f.u./ml) as SNI* log (units/ml) < 2 2-3 3-4 4-5 5 -6 6-7 7-8 < 2 2-3 3-4 4-5 5-6 < I I-2 2-3 3-4
Numbers of mice indicating blood activity Administration infection ( Fig. 1) and at about the time that cyclophosphamide ceases to modify primary or secondary responses or depress antibody synthesis. The bars in Fig. 2b show the primary and secondary potentiations from parallel experiments in which cyclophosphamide was administered in multiple doses (3 mg i.p.) on days -3, o, +7 and + I4 with respect to virus infection on day o. The observed potentiations of disease were evidently due almost entirely to the drug dose applied at the most critical time of day o (3 h before virus).
Viraemia, antibody and interferon
In order to explore further the influence of cyclophosphamide treatment upon the course of viraemia and the development of antibody and interferon activity, groups of about 20 A2G mice were given 6 x io 3 p.f.u, of the avirulent strain A774.C1 of SFV.[These mice also received 4 mg i.p. of cyclophosphamide at 3 days or 3 h before virus infection, or at 3 days after virus infection. In this experiment the mice were 9o or I5o days old in order to minimize any drug toxicity. Each mouse was bled sequentially at 2, 7 and 29 days after virus infection, and their individual samples were assayed for infectivity, neutralizing antibody and interferon activity.
The responses to lethal challenge at 3o days after primary avirulent infection were close to those shown in Fig. 2 (o; secondary potentiation) with maximal effect of 23 % susceptibility to lethal challenge for cyclophosphamide administered at day o, and only o to 7 ~o at day -3 or +3-
Other results are presented in Table I as distributions of the numbers of mice indicating particular levels of the three blood activities. This form of presentation (Bradish & Allner, 1972 ) is necessary in view of the wide range of variation in activity levels, and of the many mice which show negligible activity and so preclude the calculation of means. Activities were No drug cyclophosphamide -2 -I + I + 2 control SNI = log (antibody activity) Day of bleeding +7 3"o-4"2 > 3-3'9 > 3 > 3 3"6-4"8 + 14
4"2-4-8 3'6-4"2 3"0-3'9 3'3-4'2 4"2-5"4 assayed with a precision of about + 0"3 log units but are grouped (Table I) for brevity in ranges of I log unit.
The results (Table I) suggest that levels of viraemia at 2 days were not modified by cyclophosphamide treatment, even when the drug was applied at 3 days or 3 h before virus infection and significantly inhibited interferon production in some mice. Interferon activity was shown in 21% (-537 -) of these mouse sera compared with 61% ({{) in the sera from mice receiving only virus.
Blood samples taken at 7 days after virus infection show, as in the controls with virus only, negligible viraemia when cyclophosphamide was applied at day -3, pronounced prolongation of viraemia for drug at day o, and reduced but not yet negligible viraemia for drug at day + 3. These results are in accord with those shown in Fig. 2 . Blood interferon activity at 7 days was significant for only 5 % (~) of mice receiving virus and cyclophosphamide, but for 24 % (~f) of those receiving virus only. Thus, as for blood samples at 2 days, the already low incidence of interferon activity was reduced about fourfold further by cyclophosphamide treatment.
Recovery of antibody activity after immunomodification
In the experiments of Table I the neutralizing activity of blood was estimated also in 29th day samples in order to show the extent of recovery of neutralizing antibody synthesis following the suppressions indicated by the 7th day samples. For mice treated with cyclophosphamide at 3 days before virus infection, the distribution of antibody activity was essentially as for untreated mice. Mice treated with cyclophosphamide at 3 h before or 3 days after infection, showed maximal suppression of antibody activity at 7 days and a recovery by 29 days to distributions of antibody levels which were still about tenfold below those in mice untreated by cyclophosphamide.
Similar results for groups of IO PR mice at 31 days old are shown in Table 2 . The maximum suppression and slowest recovery of humoral antibody activity was obtained when cyclophosphamide was given at about I day after infection by lO 6 p.f.u.i.p, of virus of avirulent strain A774.CI.
Taken together, the several results of distributions of infectivity and antibody or interferon activity show that cyclophosphamide has a maximal effect, notably upon antibody synthesis and memory, when administered within 24 to 48 h of virus infection. By 3 days after virus infection the further sites then involved in virus processing are increasingly insensitive. It must be emphasized, as will be discussed, that despite this evident sensitivity of precursor cells stimulated and effective within the first 48 h of virus infection, the consequent changes in humoral antibody activity are not detectable until about the 3rd day and only regularly significant at the 5th day or later. Viraemia at 7th day as log (p.f.u./ml blood) 
Individuality of host responses and lack of correlation with viraemia or antibody synthesis
The previous results have demonstrated group trends in the levels of antibody activity and viraemia in relation to the associated changes in the incidence of primary death or protection against challenge. In order to extend these observations to the individual level, groups of about 4o mice at 3z days old were given 4 mg i.p. of cyclophosphamide at I or 2 days before virus infection, or at I or 2 days after virus infection. Infection in these groups and in a control group was by lO 6 p.f.u.i.p, of the avirulent strain A774.CI of SFV. At the 7th day after infection all animals were bled individually for assay of viraemia and antibody activity. At I4 days after primary infection all animals were challenged by IOO LDs0 i.c. of the virulent LIo.CI strain and observed for response during the following 40 days. This early and more severe central challenge was chosen to sharpen the distinction between protected (P) and challenge-susceptible (S) animals.
The results shown in Fig. 3 have been arranged to show for each mouse the relationships between the four statements of time of drug administration, type of response, and level of viraemia and neutralizing antibody in serum at the critical 7th day. Of the control mice which received avirulent virus without cyclophosphamide (filled symbols O, m, A), all had high serum neutralizing activity (SNI ~ 3"9)without detectable viraemia (< 3o p.f.u./ml blood), except for two with about Io 4 p.f.u./ml blood. Of 38 mice which received cyclophosphamide I or 2 days before virus (open symbols ©, [], A), 34 had significant serum neutralizing activity (SNI ,-~ 2.7) without detectable viraemia (< 3o p.f.u./ml blood). This situation was reversed in the 4o mice which received cyclophosphamide I or 2 days after virus (centred symbols Q, F~, ±) and which then had high viraemia (~ 2ooo p.f.u./ml blood) without detectable serum neutralizing activity (SNI < 1.5).
These results demonstrate again the two patterns of immunomodification associated with high viraemia and negligible antibody activity (for cyclophosphamide after virus) or with high antibody activity and negligible viraemia (for cyclophosphamide before virus).
Despite these distinct time-controlled influences of cyclophosphamide on viraemia and antibody level, the increased incidence of primary death (circles in Fig. 2 , O, ©, Q) was similar at 35 to 48 % (primary potentiation) in both cyclophosphamide-treated groups. Similarly the incidence of challenge susceptibility (squares in Fig. 3 ) or of protection (triangles in Fig. 3 ) appeared to be unrelated to the great changes observed in the levels of antibody activity or viraemia. There was thus no correlation of high or low viraemia or antibody activity with the individual response of death or protection.
It appears from these results that if the delay or depression of antibody synthesis is a determinant in the expression of virulence, then this occurs in tissue sites or in classes of immunoglobulins which have not been expressed through assay of humoral activity on the 7th day.
Primary and secondary potentiation, route of infection and rate of response
The aggregated scores for the numbers of mice showing primary death (D), protection (P) or challenge susceptibility (S) are shown in Table 3 for a number of conditions of route of infection (i.p. or i.c.) with IOOO to Io n p.f.u, of virulent or avirulent strains of SFV. This enables the status of mice infected by avirulent virus after immunomodification to be compared with that of virulent or avirulent infected control mice. Results are shown for cyclophosphamide administered once at 3 days before infection so that in this mode of immunomodification there were minimal changes in the patterns of humoral antibody activity or viraemia (Fig. 2) . The potentiation of disease following i.p. infection was largely primary (leading to primary death) rather than secondary (leading to susceptibility to later challenge).
About 6o % of mice showed enhanced responses due to cyclophosphamide following either i.p. or i.c. infection by avirulent virus. Infections by the i.c. route were associated with a significantly greater impairment of the protective response (secondary potentiation). This is consistent with the much slower development of protection following primary i.c. infection (Bradish & Allner, I972; Bradish et al. I972 ) and the consequently higher incidence of death following challenge (S) when levels of protection were depressed.
The median times of primary death are also entered in Table 3 and it is significant that survival following primary avirulent infection was the same for both routes of infection and was not altered significantly by immunomodification. Thus the primary potentiation defined by the higher incidence of primary deaths was not associated with a shortening of the survival times to the 2"5 or 6 days shown by mice infected i.e. or i.p. by the virulent LIo.CI strain of SFV. Similarly the median times of death following challenge (shown in S columns of Table 3 ) approximate to that of a primary' avirulent' lethality and are clearly not as early as the 6 days shown for the control primary 'virulent' lethality.
If the infection caused by the virulent strain LI o.C ~ is considered as apotentiated avirulent infection, then the virulent infection i.e. or i.p. is equivalent to a primary potentiation of 76 to 88 %, compared with 27 to 48 % for cyclophosphamide. Thus the virulent strains of Virus, virulence and immunomodification 235 SFV probably induce a distinct and more efficient invasion of the CNS, or fail to induce an efficient and early protective response. This is shown further (Table 3) by the slower deaths following primary avirulent or potentiated avirulent infections in which survival is extended to 11 or 12 days from that of 2"5 or 6 days for direct i.e. or i.p. virulent infections. Thus although immunomodification by cyclophosphamide increases the incidence of primary deaths from about lO to 6o %, and weakens the development of immunity, some protective factors are still residually effective. A similar limitation probably also arises in hamsters (Jahrling, Dendy & Eddy, 1974) . DISCUSSION A central problem in the expression of virulence by serologically indistinguishable strains of virus is the mechanism by which the host discriminates between infecting virus particles of virulent or avirulent potential. This is complicated by the need to specify virus-cell interactions within the first 48 or 72 h of infection and 2 to 5 days before differences first become detectable in the blood or tissue levels of infectivity, antigens, antibodies, or informed cells.
The use of 'immunomodifying' drugs allows some reduction of this blind period, since, if an appropriate dose is administered once to groups of animals at various times before or after a standard virus infection, then the curves showing the modified responses (Fig. 2) indicate the consequences of early events at particular target sites (Nathanson & Cole, 197o, 1971) . This is complicated, as shown in this paper, by multiple modes of drug action (Makinodan, Santos & Quinn, I97O) and by the diversity of indicators of host response of which some, like viraemia and antibody activity, may be only incidental to the expression of virulence. Thus, in these studies with cyclophosphamide, the time of drug administration determined the mode of immunomodification and the expression of virulence. This was expressed by the enhancement of primary lethality (primary potentiation) or by the increased susceptibility to subsequent lethal challenge (secondary potentiation). But these distinct modifications of the response of the individual were not determined by, or correlated with, the marked changes in the course of viraemia or antibody synthesis.
Any consideration of the modification by drugs of the course of virus infection is limited by the general toxicity and side effects which may accompany more specific mechanisms. Such uncertainties are reduced if single and lower doses are administered at optimal times during the course of infection, and if drug administration outside this optimal time range is without significant effect. Thus, in the present experiments, at least 95 % of mice showed no effect on the course of infection when cyclophosphamide was given later than about 4 days after virus infection. This indication of the specific influence of drug only on sites actively involved in the processing of virus is supported by the complementary studies with other drugs reported in the following paper (Bradish et al. 1975 ) .
The observation that critical virus-cell interactions ceased to be drug sensitive within about 3 days of infection by virus is interpreted as showing the latest mean time for which such virus-cell interactions and associated feed-back regulations were able to modify the otherwise progressive invasion of the CNS and so determine an avirulent course of infection. For normal mice this is 12 to 24 h before (Fig. 1 ) the brain infectivity begins to fall in avirulent, but not virulent, infections and about 12 h after the unrelated inhibition of viraemia and interferon activity.
The indication by Turk & Poulter (PouRer & Turk, 1972; Turk & Poulter, I972; Turk, 1973) that cyclophosphamide in mice selectively depresses B lymphocytes without a similar effect on T Iymphocytes, suggests an association of potentiation of disease with suppression of antibody synthesis and persistence of viraemia, particularly for replicating antigens which may by-pass the cooperative function of T cells. This is in accord with our observations on the pattern of reduced resistance to challenge (secondary potentiation) and the associated impairment of antibody synthesis and recovery (memory) which are maximally sensitive to the effects of cyclophosphamide given within the first 48 h following virus infection.
In contrast to this, enhanced initial lethality (primary potentiation) continued at about 5o ~o to 60 ~o in the mode of immunomodification associated with continued antibody synthesis and prompt suppression of viraemia. This occurred when cyclophosphamide was administered at up to 3 or more days before virus, and implies a prolonged effect upon a more sensitive cell population which is less involved in later antibody synthesis. Thus in this mode of immunomodification T cells may be more sensitive than B cells (as also for 1-asparaginase in the following paper). An inhibition of proliferating T cells may thus determine the primary potentiation, and of proliferating B cells the secondary potentiation.
These observations for cyclophosphamide confirm its classification (Class III : Makinodan et al. 197o) as an agent which is effective when administered before or after stimulation by antigen, and particularly at up to 2 days after antigen when proliferative and differentiating events of the immune response are most sensitive. That this also applies to an antigen which is a replicating virus, and without enhancement of its primary efficiency of infection or production of interferon, again suggests that cyclophosphamide acts through inhibition of the earliest secondary proliferations and feed-back regulations.
The more direct test of these interpretations by adoptive immunity requires the transfer to a recipient mouse of T or B cells derived from a donor infected with virus less than 3 or 4 days previously. In tests with strains of Venezuelan equine encephalomyelitis virus and the present strains of SFV, Rabinowitz and his associates (Adler & Rabinowitz, 1973; Rabinowitz & Adler, I973; Rabinowitz & Proctor, I974) have studied the role of spleen cells harvested from donors infected from 4 to 36 days previously. For the VEEV system adoptive immunity and in vitro reactivity were minimal at 4 days and maximal at 8 days. Our own studies in the SFV system show a slight adoptive immunity as early as 4 days which depends critically upon the time and level of challenge and the number of cells transferred. Jahrling et al. (1974) have studied immunosuppression in 7 weeks old hamsters treated with cyclophosphamide at 16 h before and at the time of s.c. infection by the avirulent TC-83 strain of Venezuelan equine encephalitis virus (VEEV). The 64 % enhancement of lethality (primary potentiation) occurred with higher and prolonged viraemia and involvement of brain, spleen and bone marrow: interferon levels may have been lower in blood and marrow. Only about 2o % primary potentiation was observed for the Pixuna strain of VEEV of intermediate virulence (Walder & Bradish, 1975) . Resistance to challenge (secondary potentiations) and the role of antibody were not studied.
The consideration of antibody activity in terms of its close inverse relationship with viraemia and its apparent unrelatedness to the outcome of infection, raises many questions on the rate, site, diversity and specificity of immunoglobulin synthesis following their differential stimulation by the array of antigens produced during virus replication (Neurath & Rubin, I971) . These questions must remain largely unanswered since, in the context of host responses within 2 or 3 days of infection, only the dominant and most avid antibody activities can be detected by conventional serological or neutralization methods. In absolute terms these methods may detect less than I ng of antibody but are still far less sensitive titan the plaque assay of virus infectivity. Thus, at the threshold of detection of virus neutralization (SNI from 0"5 to I'5) in serum at 2 days after infection, the concentration of specific immunoglobulin molecules may already be about Iog/ml (Fitzgeorge & Bradish, I973; Allner et al. 1974). There is thus a problem of causality since early antibody effects probably occur in vivo at concentrations far below that for in vitro detection. It is thus difficult to relate early intracellular or humoral activity to the roles of antibodies, interferons, and serum protective or other soluble regulatory factors (Thind & Price, 1968) .
